# US 2025/0049712 A1 · High-efficiency and low-toxicity dna and rna lipid delivery carrier

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0049712 A1
- Document ID: US20250049712A1
- Status: Published application
- Kind: A1
- Application number: 18/721,013
- Filed: 2022-12-15
- Published: 2025-02-13
- Earliest claimed: 2021-12-15
- Assignees: Revivo Therapeutics Co., Ltd.
- Applicants: Revivo Therapeutics Co., Ltd.
- Inventors: Yanfang Cui; Shuaijie Ji; Baoqian Zhang
- Web page: https://patentgrep.com/patent/US20250049712A1

## CPC

- A61K 9/1271: Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911})
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- C07C 229/16: to carbon atoms of hydrocarbon radicals substituted by amino or carboxyl groups, e.g. ethylenediamine-tetra-acetic acid, iminodiacetic acids
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES

## Abstract

Provided in the present invention is a high-efficiency and low-toxicity DNA and RNA lipid delivery carrier. In order to enrich the types of nucleic acid drug delivery carriers, improve the in-vivo delivery and expression effects of the nucleic acid drug and reduce the toxicity and side effects, a new ionizable lipid compound having a special structure is provided in the present invention. The compound has a good binding effect with a negatively-charged nucleic acid, which effectively prevents the premature degradation of the nucleic acid by a nuclease in a cell and facilitates the passage of a liposome loaded with the nucleic acid through a cell membrane. Effective degradation and rapid removal can be achieved, the toxicity and side effects of the nucleic acid drug are reduced, and a nucleic acid drug delivery carrier truly having a high transfection efficiency, a high expression level and a low toxicity can be formed.

## Claims

### Claim 1

An ionizable lipid compound shown in general formula (I) or general formula (II),
wherein,
in general formula (I), G1 is C1-C10 linear alkylidene, G2 is —OC(═O)R, —C(═O)OR or —C(═O)NHR, R is C5-C20 linear alkyl or
R1 is hydrogen, methyl, ethyl, or isopropyl, m is an integer between 1˜10, n is an integer between 1˜5, and f is an integer between 1˜5;
in general formula (II), G3 is C1-C10 linear alkylidene, G4 is —OC(═O)R′, —C(═O)OR′ or —C(═O)NHR′, R′ is
R2 and R3 are independently hydrogen, methyl, ethyl, or isopropyl, q is an integer between 1˜3.

### Claim 2 (depends on 1)

The ionizable lipid compound according to claim 1, wherein G1 is C2-C8 linear alkylidene;
and/or, G3 is C5-C10 linear alkylidene;
and/or, R1 is hydrogen;
and/or, m is an integer between 3˜8;
and/or, f is an integer between 1˜4;
and/or, R is C5-C15 linear alkyl or R1 or

### Claim 3 (depends on 2)

The ionizable lipid compound according to claim 2, wherein m is an integer between 4˜6 and/or f is 2 or 3.

### Claim 4 (depends on 1)

The ionizable lipid compound according to claim 1, wherein G2 is —C(═O)OR and/or, G4 is —C(═O)OR′;
and/or, R2 is methyl, and R3 is hydrogen.

### Claim 5 (depends on 1)

The ionizable lipid compound according to claim 1, wherein the ionizable lipid compound is one or more of the following compounds:

### Claim 6 (depends on 1)

A delivery carrier comprising one or more of ionizable lipid compounds shown in general formula (I) and general formula (II) of claim 1.

### Claim 7 (depends on 6)

The delivery carrier according to claim 6, wherein the delivery carrier further comprises a helper molecule, and the feeding molar ratio of the ionizable lipid compound to the helper molecule is (0.1˜1):(0.1˜1).

### Claim 8 (depends on 7)

The delivery carrier according to claim 7, wherein the helper molecule comprises one or more of synthetic or naturally sourced helper lipid or lipoid molecules, animal sources of any species and any type of cells or vesicles, polypeptide molecules, polymer molecules, carbohydrate molecules or inorganic substances.

### Claim 9 (depends on 8)

The delivery carrier according to claim 8, wherein the helper molecule comprises one or more of cholesterol, calcipotriol, stigmasterol, lupeol, β-sitosterol, betulin, ursolic acid, oleanolic acid, dioleoyl phosphatidylcholine, distearoyl phosphatidylcholine, 1-stearoyl-2-oleoyl phosphatidylcholine, dioleoyl phosphatidylethanolamine, (1,2-dioleyloxy-propyl) trimethylammonium chloride, didecyl dimethyl ammonium bromide, 1,2-dimyristoyl-sn-glycero-3-ethyl phosphocholine, dipalmitoyl phosphatidylethanolamine-methoxy polyethylene glycol 5000, distearoyl phosphatidylethanolamine-polyethylene glycol 2000, activated carbon, silica and calcium phosphate.

### Claim 10 (depends on 7)

The delivery carrier according to claim 7, wherein the ionizable lipid compound and/or the helper molecule is modified with a targeting substance, and the targeting substance comprises one or more of folic acid, single-chain antibodies and targeting polypeptides.

### Claim 11 (depends on 6)

The delivery carrier according to claim 6, wherein the delivery carrier is a lipid nanoparticle, the lipid nanoparticle has a particle size of 50 nm˜200 nm; and/or, the lipid nanoparticle has a polydispersity index of <0.4.

### Claim 12 (depends on 11)

The delivery carrier according to claim 11, wherein the delivery carrier is able to deliver a nucleic acid molecule, and the nucleic acid molecule comprises, but is not limited to, one or more of plasmid DNA (pDNA), siRNA, ASO, and mRNA; and/or, the mass ratio of the nucleic acid molecule to the delivery carrier is 1:(5˜50).

### Claim 13 (depends on 9)

The delivery carrier according to claim 9, wherein the delivery carrier and the nucleic acid molecule constitute a nucleic acid drug composition, the nucleic acid drug composition further comprising a pharmaceutical available additive, and the additive comprises one or more of an excipient, a stabilizer, and a diluent.

### Claim 14 (depends on 13)

The delivery carrier according to claim 13, wherein the amount of the additive accounts for 1%˜20% of the total mass of the drug composition.

### Claim 15 (depends on 6)

The delivery carrier according to claim 6 wherein the delivery carrier or the nucleic acid drug composition is a freeze-dried powder or an injection, which is locally administered by microneedles, injection or perfusion through muscle, subcutaneous, endothelium or intra-tumor, or is administered by intravenous injection.

### Claim 16 (depends on 6)

A method for in vivo delivery of nucleic acid molecules comprising administering the delivery carrier according to claim 6 to deliver the nucleic acid molecules to the body of a subject.

### Claim 17 (depends on 16)

The method for in vivo delivery of nucleic acid molecules according to claim 16, wherein the subject is a mammal.

### Claim 18 (depends on 16)

The method for in vivo delivery of nucleic acid molecules according to claim 16, wherein the subject is human.

### Claim 19 (depends on 6)

The delivery carrier according to claim 6, wherein the ionizable lipid compound is one or more of the following compounds:

### Claim 20 (depends on 16)

The method for in vivo delivery of nucleic acid molecules according to claim 16, wherein the delivery carrier comprises one or more of the following ionizable lipid compounds:
